{"name":"Philogen S.p.A.","slug":"philogen-spa","ticker":"","exchange":"","domain":"philogenspa.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":12,"colorKey":"oncology","drugs":[{"name":"L19TNF and CCNU","genericName":"L19TNF and CCNU","slug":"l19tnf-and-ccnu","indication":"Other","status":"phase_2"},{"name":"F16IL2 in combination with paclitaxel","genericName":"F16IL2 in combination with paclitaxel","slug":"f16il2-in-combination-with-paclitaxel","indication":"Other","status":"phase_1"},{"name":"L19TNF and CCNU in recurrent astrocytoma","genericName":"L19TNF and CCNU in recurrent astrocytoma","slug":"l19tnf-and-ccnu-in-recurrent-astrocytoma","indication":"Other","status":"phase_2"},{"name":"Daromun","genericName":"Daromun","slug":"daromun","indication":"Other","status":"phase_3"},{"name":"L19IL2 - Ph I","genericName":"L19IL2 - Ph I","slug":"l19il2-ph-i","indication":"Other","status":"phase_1"},{"name":"L19TNF","genericName":"L19TNF","slug":"l19tnf","indication":"Other","status":"phase_2"},{"name":"L19TNF and TMZ","genericName":"L19TNF and TMZ","slug":"l19tnf-and-tmz","indication":"Glioblastoma","status":"phase_2"},{"name":"L19TNF monotherapy","genericName":"L19TNF monotherapy","slug":"l19tnf-monotherapy","indication":"Other","status":"phase_2"},{"name":"Nivolumab, fixed dose","genericName":"Nivolumab, fixed dose","slug":"nivolumab-fixed-dose","indication":"Other","status":"phase_1"},{"name":"[68Ga]Ga-OncoACP3","genericName":"[68Ga]Ga-OncoACP3","slug":"68ga-ga-oncoacp3","indication":"Other","status":"phase_1"},{"name":"[68Ga]Ga-OncoCAIX","genericName":"[68Ga]Ga-OncoCAIX","slug":"68ga-ga-oncocaix","indication":"Other","status":"phase_1"},{"name":"[68Ga]Ga-OncoFAP administration","genericName":"[68Ga]Ga-OncoFAP administration","slug":"68ga-ga-oncofap-administration","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Intratumoral injections of L19IL2","genericName":"Intratumoral injections of L19IL2","slug":"intratumoral-injections-of-l19il2","indication":"Treatment of various cancers","status":"phase_2"},{"name":"L19IL2 + L19TNF","genericName":"L19IL2 + L19TNF","slug":"l19il2-l19tnf","indication":"Metastatic melanoma","status":"phase_3"}]}],"pipeline":[{"name":"L19TNF and CCNU","genericName":"L19TNF and CCNU","slug":"l19tnf-and-ccnu","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"F16IL2 in combination with paclitaxel","genericName":"F16IL2 in combination with paclitaxel","slug":"f16il2-in-combination-with-paclitaxel","phase":"phase_1","mechanism":"F16IL2 targets tumor vasculature via antibody fragment F16 and delivers IL-2 to stimulate immune response at the tumor site, combined with paclitaxel chemotherapy.","indications":[],"catalyst":""},{"name":"Intratumoral injections of L19IL2","genericName":"Intratumoral injections of L19IL2","slug":"intratumoral-injections-of-l19il2","phase":"phase_2","mechanism":"L19IL2 is an immunocytokine that targets the EDB domain of fibronectin, which is overexpressed in tumor vasculature, and delivers IL-2 to the tumor microenvironment to stimulate an anti-tumor immune response.","indications":["Treatment of various cancers"],"catalyst":""},{"name":"L19TNF and CCNU in recurrent astrocytoma","genericName":"L19TNF and CCNU in recurrent astrocytoma","slug":"l19tnf-and-ccnu-in-recurrent-astrocytoma","phase":"phase_2","mechanism":"L19TNF delivers tumor necrosis factor to tumor blood vessels via antibody targeting, combined with CCNU's DNA alkylation to kill cancer cells.","indications":[],"catalyst":""},{"name":"Daromun","genericName":"Daromun","slug":"daromun","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"L19IL2 + L19TNF","genericName":"L19IL2 + L19TNF","slug":"l19il2-l19tnf","phase":"phase_3","mechanism":"L19IL2 + L19TNF is a bispecific antibody-cytokine fusion combination that targets tumor vasculature via the L19 antibody while delivering IL-2 and TNF directly to the tumor microenvironment.","indications":["Metastatic melanoma","Metastatic renal cell carcinoma"],"catalyst":""},{"name":"L19IL2 - Ph I","genericName":"L19IL2 - Ph I","slug":"l19il2-ph-i","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"L19TNF","genericName":"L19TNF","slug":"l19tnf","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"L19TNF and TMZ","genericName":"L19TNF and TMZ","slug":"l19tnf-and-tmz","phase":"phase_2","mechanism":"TNF-alpha inhibitor","indications":["Glioblastoma"],"catalyst":""},{"name":"L19TNF monotherapy","genericName":"L19TNF monotherapy","slug":"l19tnf-monotherapy","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Nivolumab, fixed dose","genericName":"Nivolumab, fixed dose","slug":"nivolumab-fixed-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[68Ga]Ga-OncoACP3","genericName":"[68Ga]Ga-OncoACP3","slug":"68ga-ga-oncoacp3","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[68Ga]Ga-OncoCAIX","genericName":"[68Ga]Ga-OncoCAIX","slug":"68ga-ga-oncocaix","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[68Ga]Ga-OncoFAP administration","genericName":"[68Ga]Ga-OncoFAP administration","slug":"68ga-ga-oncofap-administration","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":14,"phaseCounts":{"phase_2":6,"phase_1":6,"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}